Impact of Histological Variants on Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Impact of Histological Variants on Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab: A Propensity Score Matching Analysis
BJU Int 2021 Jun 10;[EPub Ahead of Print], M Kobayashi, S Narita, Y Matsui, S Kanda, Y Hidaka, H Abe, T Tsuzuki, K Ito, T Kojima, M Kato, S Hatakeyama, Y Matsushita, S Naito, M Shiga, M Miyake, Y Muro, S Nakanishi, Y Kato, T Shibuya, T Hayashi, H Yasumoto, T Yoshida, M Uemura, R Taoka, M Kamiyama, S Morita, T Habuchi, O Ogawa, H Nishiyama, H Kitamura, T KobayashiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.